The cytotoxicity of AZD5991 in a panel of MCL primary samples from patients who were naïve, sensitive, or resistant to single or multiple treatments of BTKi, venetoclax, and anti-CD19 CAR T-cell therapy was further evaluated (Table S2). Here, CD19 is linked to mantle cell lymphoma.